An interventional study of Transcatheter Mitral Valve Repair in Degenerative Mitral Regurgitation, sponsored by Vesalius Cardiovascular Inc.. Recruiting at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Vesalius Cardiovascular Inc. · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Mitral Valve Insufficiency with a site in Canada — 10 open to participants now, 23 under way, 1 of them phase 3. Mitral Valve Insufficiency · Canada.
Among the 47 studies in Mitral Valve Insufficiency with a site in Canada, this one is the 32nd largest by planned enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2026, is one of 26 with no phase, reaches primary completion later than 22 of the 22 other live ones, and was the 46th registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →10 of the 47 studies in Mitral Valve Insufficiency with a site in Canada are open now. Recruiting first, the newest first:
Jonathan Beaudoin · Sites in Canada
Ages 18–85
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
4C Medical Technologies, Inc. · Sites in Canada, United States, France and 4 more countries
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in Canada, United States
Ages 18+
Abbott Medical Devices · Sites in Canada, United States
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 4
First in 2006; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5 is below the median of 69 across 280 interventional studies indexed under Mitral Valve Insufficiency.
Median enrollment 130 across the 35 interventional studies, 404 across the 12 observational. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 47 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Vesalius Cardiovascular Inc. as lead sponsor.
Vesalius Cardiovascular Inc. has 1 study filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
7 of the studies in Mitral Valve Insufficiency with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06816888Ottawa Heart Institute Research CorporationImpact of Automatic Prompts in Echocardiographic Reports on Referral to Cardiology | 2026-12-01 |
| NCT05061004Abbott Medical DevicesCephea Early Feasibility Study | 2026-12-31 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT03242642Medtronic CardiovascularTranscatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. | 2027-06 |
| NCT03066050Icahn School of Medicine at Mount SinaiLong Term Follow Up for CTSN Mitral Valve Repair Studies | 2027-07-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 47 studies in Mitral Valve Insufficiency with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This first-in-human study evaluates the safety and performance of the Vesalius Transcatheter Mitral Valve Repair (TMVr) System in patients with degenerative mitral regurgitation. The study will enroll patients who are at high or prohibitive risk for conventional surgical repair or replacement of the mitral valve. Participants will receive implantation of the Vesalius TMVr System and will be followed to assess clinical outcomes, device performance, and any adverse events.
This first-in-human study is designed to evaluate the safety and performance of the Vesalius Transcatheter Mitral Valve Repair (TMVr) System in patients with symptomatic, severe or moderate-to-severe degenerative mitral regurgitation who are at elevated surgical risk. The study will enroll up to five patients in Canada to assess procedural feasibility, technical performance, and short-term clinical outcomes following device implantation. Endpoints are based on Mitral Valve Academic Research Consortium (MVARC) definitions, including measures of procedural and device success, freedom from major adverse events, and technical achievement of device deployment. Safety, functional, and hemodynamic parameters will be monitored at predefined intervals, and follow-up will include assessment of valve function, adverse events, and device performance. This study will provide preliminary data to support the further development and evaluation of the Vesalius TMVr System.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will undergo implantation with the Vesalius Transcatheter Mitral Valve Repair (TMVr) System according to the study protocol. All procedures will be performed by trained interventional cardiologists, and participants will be followed for safety, device performance, and clinical outcomes at predefined intervals.
Device: Transcatheter Mitral Valve Repair
The Vesalius Transcatheter Mitral Valve Repair (TMVr) System is a novel transcatheter device designed to percutaneously deliver an implant to repair the native mitral valve in patients with degenerative mitral regurgitation. The system uses an adjustable ePTFE net to reduce or eliminate mitral regurgitation. The device is delivered via a minimally invasive transcatheter approach, allowing precise positioning and deployment in high-risk patients not suitable for conventional surgery.
Safety - Number of Participants Experiencing All-Cause Mortality
Number of participants experiencing all-cause mortality post-implant, prior to discharge, and through the 30-day follow-up period.
Time frame: 30 Days
Number of Participants Achieving Technical Success
Number of participants achieving successful delivery and positioning of the device, absence of procedural mortality, and freedom from emergency cardiovascular surgery or reintervention related to the device through procedure exit.
Time frame: Measured at Day 0 (Procedure Exit)
Number of participants Achieving Device Success
Number of patients achieving successful deployment and correct anatomical positioning of the device, absence of procedural mortality or stroke, and freedom from unplanned surgical or interventional procedures related to the device through 30 days.
Time frame: 30 Days
Number of Participants by Mitral Regurgitation (MR) Severity Grade
Assessment of MR severity evaluated by transthoracic/transesophageal echocardiography (TTE/TEE). MR severity is categorized using standard clinical grading: Grade 0 (None/Trace), Grade 1+ (Mild), Grade 2+ (Moderate), Grade 3+ (Severe), and Grade 4+ (Very Severe). Higher grades indicate worse outcome severity.
Time frame: 30 Days
Number of Participants Experiencing Major Adverse Events (MAE)
Occurrence of serious cardiovascular, cerebrovascular, or renal events related to the device or procedure.
Time frame: 30 Days
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Apr 2032, 68 months later.
Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 68 months is above that.
Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.